Lloyd Diamond, CEO Bonesupport, “Manufactures & Develops Novel Bone Substitute for Healthy or Infected Disease Bone”

Bonesupport Website: http://www.bonesupport.com/

Bonesupport is a Scandinavian medical technology company dedicated to the development of injectable osteoconductive biomaterials for the treatment of fragility fractures caused by osteoporosis, and bone voids or gaps caused by trauma, disease or related to surgical procedures i.e. disease, benign tumors, fracture malunion, augmentation of fracture repair. SNNLive spoke with Lloyd Diamond, CEO of Bonesupport at the 6th Annual Sachs European Life Sciences CEO Forum 2013 in Zurich, Switzerland. “We’re a privately held company in Sweden. We manufacture and develop a novel bone substitute that can be used in healthy bone or infected disease bone”, Mr. Diamond begins, ”We estimate its roughly a $1 billion market and the primary segments we focus on are trauma surgery, osteomyelitis or bone infection and patients with osteoporosis.”

“We already have approval in the US and in Europe, and we are actively selling in both markets,” where the company markets their products by, “we usually deal directly with hospitals and physicians. We’ve created alliances with major teaching centers both in Europe and the US and we also work with patient advocacy groups.” Shelly goes on to ask Mr. Diamond what separates Bonesupport from the rest of the pack, “I think in our space there are a lot of different products that say that they are good bone substitutes, but none of them really have any good clinical evidence. We have over 35 published studies, or preclinical studies and we’ve been doing research on our product for the last 12 years focused only on our product platform, which is called Cerament.”

“In fact, the market for trauma alone is showing double digit growth, 10-12%. Osteomyelitis market, for bone infection, is growing at least 20%. More and more patients are coming in with traumatic injuries, they get become infected over time and they require multiple surgeries…in the area of diabetes, as you know, diabetic patients often times suffer limb problems, which ultimately lead to amputation. With Cerament and our antibiotic eluting product, it can actually be used in end-stage limb disease to actually prevent amputation,” Mr. Diamond explains. On reimbursement, “It’s there in the major markets. We actually fit into existing codes. In the US, these type of products are highly reimbursed and in Europe they have specific codes for it as well.” For more information about Bonesupport, check out their website. SNNLive welcomes Lloyd Diamond, CEO of Bonesupport.